2023 Clinical Trials Conditions Patients 
Project CBD
MARCH 21, 2023
She was upset with herself for being so careless and concerned that the condition would persist. For many other people of all ages, tinnitus is indeed a chronic condition that has nothing to do with loud ‘80s cover bands in small clubs. And it’s not just ringing.
Veriheal
MARCH 2, 2024
In December of 2023, the country recently made a new move towards reform that could stimulate the cannabidiol (CBD) industry and provide many patients, such as those with epilepsy , with access to potentially life-changing medical treatments. and Europe to treat severe epilepsy, as well as other medical conditions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
OCTOBER 4, 2021
One of the known beneficial uses of psilocybin is as a palliative care tool for patients with advanced illness who suffer from anxiety and/or depression. A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions.
Veriheal
MARCH 20, 2023
Both Colorado and Oregon allow patients to take psilocybin under the supervision of regulated and licensed “healing centers.” The state bill would start the process of legalizing centers for veterans and first responders to receive psilocybin and MDMA (a synthetic psychedelic) to treat mental health conditions like PTSD. Missouri Rep.
Cannabis Law Report
MAY 31, 2022
The first path, that of traditional medicine, currently offers patients limited options. The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. 2022 Active FDA Clinical Trials and State-Regulated Systems.
Cannabis Law Report
APRIL 21, 2022
The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public .
Cannabis Law Report
MAY 12, 2022
Lophora has previously secured grant funding from the BioInovation Institute (Novo Nordisk Foundation) and continues to characterise its lead candidates, aiming to initiate clinical trials in 2023. Lophora expects LPH-5 to be IND ready in Q4 2022 and plans to begin first-in-human trials in 2023.
Expert insights. Personalized for you.
144 
Let's personalize your content